Peregrine Pharma concludes patient recruitment in Bavituximab Phase Ib trial
In previous studies, Bavituximab when administered as monotherapy, demonstrated positive results on therapy antiviral activity of up to 1.5 log viral load reduction. The primary endpoints of the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.